Cost of Revenue Comparison: Dr. Reddy's Laboratories Limited vs Lantheus Holdings, Inc.

Cost of Revenue: Dr. Reddy's vs. Lantheus - A Decade in Review

__timestampDr. Reddy's Laboratories LimitedLantheus Holdings, Inc.
Wednesday, January 1, 201456369000000176081000
Thursday, January 1, 201562786000000157939000
Friday, January 1, 201662427000000164073000
Sunday, January 1, 201762453000000169243000
Monday, January 1, 201865724000000168489000
Tuesday, January 1, 201970421000000172526000
Wednesday, January 1, 202080591000000200649000
Friday, January 1, 202186645000000237513000
Saturday, January 1, 2022100551000000353358000
Sunday, January 1, 202342907000000586886000
Monday, January 1, 2024115557000000
Loading chart...

Data in motion

A Tale of Two Companies: Cost of Revenue Analysis

In the ever-evolving pharmaceutical and healthcare industry, understanding cost dynamics is crucial. Dr. Reddy's Laboratories Limited, a global pharmaceutical giant, and Lantheus Holdings, Inc., a leader in diagnostic imaging, present a fascinating study in contrasts. From 2014 to 2023, Dr. Reddy's Laboratories consistently reported a cost of revenue that dwarfed Lantheus Holdings by over 99%. This disparity highlights the scale and operational differences between the two companies. Notably, Dr. Reddy's Laboratories saw a significant increase in 2024, with costs surging by approximately 15% from 2022, while Lantheus Holdings' data for 2024 remains unavailable. This missing data underscores the challenges in financial forecasting and the importance of comprehensive data analysis. As the industry continues to grow, these insights provide a window into the financial strategies of leading companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025